Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. When our experienced team carry out your assay by using optimized and validated protocols of safety/toxicity evaluation, our clients can benefit from the efficiency and accuracy of a dedicated facility.
Cellular adoptive immunotherapy has been shown to mediate the regression of large tumors. A limitation of this treatment is the need to isolate and expand tumor-reactive lymphocytes that preexist in the patient, which can be overcome by transducing genes encoding antitumor T-cell receptor (TCR), thus providing an alternative source of tumor-specific lymphocytes.
Although we are all aware of the benefits of the immune cell defense against diseases factors, it is also true that in some cases, severe acute and chronic damage can be inflicted on the host by these same cells. The concept behind adoptive T-cell transfer is to greatly enhance the T cell repertoire against cancer by administering tumor-reactive T cells expanded and activated in vitro. So it should be no surprise that toxicities from these cells could also be enhanced. The toxicities encountered are of four types: 1) The host immunosuppression used to enhance function and engraftment of transferred T cells can have its own side effects, 2) Vigorous T cell function immediately after administration can cause acute cytokine toxicity or "cytokine storm", 3) expression of the target antigen on some normal tissues can cause an "on target, off tumor" autoimmune injury, and 4) Aberrant reactivities can be introduced into T cells by modification of their receptors. Evaluation of the toxicity on animal models is essential to assure the safety and right of subjects. With extensive experience on preclinical in vivo research and project management, Creative Biolabs provides TCR-T cell toxicity evaluation service by utilizing appropriate models, designing comprehensive research practices and handling high-quality in vivo studies.
Fig.1 Safety/Toxicity Evaluation of TCRs
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
